In 2015, the WHO reported that approximately onethird of deaths globally were attributable to cardiovascular disease (CVD) 1 . Atherosclerosis, an inflammatory disorder of the vasculature, is the primary cause of cardiovascular events, including myocardial infarction (MI) and stroke. Given the increase in the prevalence of obesity and diabetes mellitus in developing countries, the global incidence of CVD is predicted to increase and impose a greater economic burden on health-care services around the world.
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Under normal healthy conditions, the metabolism and transport of cholesterol are highly regulated. The development of atherosclerosis can progress when these homeostatic mechanisms become unbalanced in favour of either increased influx or decreased efflux of cholesterol in cells. Within the blood, there are several lipoproteins that each have a different function in lipid transportation. LDL is one of the most important lipoproteins found in the bloodstream and functions to transport cholesterol from the liver to the peripheral tissues 2 . LDL particles enter cells primarily by receptor-mediated endocytosis using the LDL receptor (LDLR). To maintain a balance in cholesterol metabolism, HDL transports excess cholesterol from the peripheral tissues back to the liver for excretion via the bile system by a process known as reverse cholesterol transport 2 . However, only 5% of biliary cholesterol is excreted through faecal matter, and the rest is reabsorbed in the intestine 2 . Given that high LDLcholesterol and low HDL-cholesterol levels have been associated with reduced endothelial function, increased LDL-cholesterol and HDL-cholesterol levels are thought to be proatherogenic and antiatherogenic, respectively 3 . Therefore, strategies for treating atherosclerosis should be aimed at lowering plasma LDL levels and increasing serum HDL levels.
Research using mouse models in the past 20 years has improved our understanding of the pathophysiology of atherosclerosis. Mice do not naturally develop atherosclerosis, but Ldlr-deficient and apolipoprotein E (Apoe)-deficient mouse models are prone to atherosclerotic lesion formation when fed a high-fat or highcholesterol diet, mimicking several aspects of the disease seen in humans. Atherosclerosis is characterized by the build-up of fatty deposits and the formation of plaques in the walls of large and medium arteries, followed by a strong immunological response to fatty deposit accumulation (FIG. 1) . This initial fatty deposit build-up in the intima of arteries, often referred to as a fatty streak, is composed of apolipoprotein B (Apob)-containing lipoproteins, in particular LDL and other lipoprotein remnants 2 . This trapped LDL can then become oxidized to form oxidized LDL (oxLDL) 2 . The presence of oxLDL within the intima of the artery triggers an inflammatory response in the neighbouring endothelial cells, which start producing proinflammatory cytokines and chemokines 2, 4 . The roles of different cytokines and chemokines in atherosclerosis have been extensively reviewed and can be generally classified as either proinflammatory or anti-inflammatory 4, 5 . After monocytes have migrated into the intima of the artery, they become exposed to macrophage colonystimulating factor and differentiate into macro phages, a process that is associated with increased expression of scavenger receptors on their cell surface 2 . The uptake of LDL via the LDLR is controlled by a negative feedback loop, whereas oxLDL uptake via scavenger receptors, such as macrophage scavenger receptor type 1 (MSR1) and CD36, is unregulated 6 . Proinflammatory cytokines can induce foam cell formation by altering the expression of key genes implicated in the regulation of cholesterol metabolism and transport, such as ABCA1, ACAT1, APOE, and MSR1 (REFS 2, 4, 5, 7, 8) . Foam cells subsequently begin to accumulate and form an initial lesion that matures into an atherosclerotic plaque 2, 4, 5, 8 . During maturation of the atherosclerosis lesion, the accumulated foam cells begin to undergo apoptosis and necrosis, which leads to release of their fatty contents into the intima of the arteries. The apoptotic cells and the fatty contents accumulate to form a lipid-rich necrotic core. During the latter stages of plaque progression, macrophages, endothelial cells, and T cells stimulate the proliferation and migration of vascular smooth muscle cells from the media to the intima of arteries, resulting in the formation of a fibrous cap over the lipid core 2, 9 . The fibrous cap is then strengthened by extra cellular matrix (ECM) produced by the vascular smooth muscle cells 2, 10 . Given that the fibrous cap stabilizes the lesion, the balance of ECM deposition and degradation is critical in dictating the clinical progression of athero sclerosis. ECM-degrading enzymes are released from macrophages that are undergoing apoptosis, shifting the balance towards ECM degradation and increasing the risk of plaque rupture 11 . Clinical symptoms of plaque development are usually not apparent until the plaque undergoes rupture. Upon rupture, platelet aggregation rapidly occurs, which can quickly impede or obstruct blood flow though the artery 2 , resulting in a coronary event.
Statins are the most commonly used cholesterollowering agent. Statins reduce the circulating LDLcholesterol level by inhibiting 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase, the enzyme involved in the rate-limiting step during cholesterol biosynthesis 12 . However, patients taking statins still harbour a discernible residual risk of a cardiovascular event and a small proportion of patients are unable to achieve target plasma cholesterol levels despite receiving the maximum recommended dose of statins 2, 13 . Furthermore, high-dose statin therapy is associated with adverse effects, such as muscle pain and hepatic abnormalities 14, 15 . Therefore, alternative therapeutics are needed that can either be taken alone or in combination with statins 2, 13 . Despite emerging therapies such as ezetimibe [16] [17] [18] and antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) [19] [20] [21] [22] and proinflammatory cytokines 23 , further research should be conducted on alternative approaches that limit inflammation and other proatherogenic changes in atherosclerosis.
One potential therapeutic avenue being explored for the prevention of atherosclerosis is the use of natural products that are thought to have anti-inflammatory properties, known as nutraceuticals. Nutraceuticals can be classified as either functional foods or dietary supplements with health benefits beyond their basic nutritional value. Diets that are rich in fruit, vegetables, fish, cereal grains, or olive oil have all been associated with cardio vascular health benefits [24] [25] [26] . The aim of this Review is to summarize the major nutraceutical components in these diets and to discuss their possible uses for the prevention of atherosclerosis using evidence from both pre clinical and clinical studies. The stages of atherosclerosis develop ment at which different nutraceuticals exert their potential beneficial effects are summarized in FIGURE 2. Omega-3 polyunsaturated fatty acids Polyunsaturated fatty acids (PUFAs) can regulate blood pressure and clotting, and are involved in the formation of eicosanoids -signalling molecules that can modulate the inflammatory response 25 . PUFAs contain two or more carbon-carbon double bonds and can be classified as either omega-6 or omega-3 depending on the position of the carbon-carbon double bond closest to the methyl terminus of the molecule 25 . Dietary intake of PUFAs is vital because they cannot be synthesized in vivo; fish oils, flax seeds, and nuts are rich sources of omega-3 PUFAs 25 , whereas vegetable oils and animal fat are the major sources of omega-6 PUFAs 25 .
The cardiovascular health benefits of omega-3 PUFAs have been described in several epidemiological and clinical studies over the past 60 years 27, 28 . The AHA recommends eating two portions of oily fish every week, in which one portion is defined as ≥100 g 29 . The AHA also advises that individuals who are unable to boost their omega-3 intake through diet alone should discuss with their doctor about the possibility of taking oral omega-3 supplements 29 . An epidemiological study published in 1980 found a reduced incidence of cardiovascular events that could be attributed to lower serum cholesterol levels in the Inuit population of Greenland, despite their diets being rich in saturated fats (in the form of fish and whale meat) and low in fruit and vegetables 30 . The omega-3 PUFAs eicosapentaenoic acid (EPA) and docosa hexaenoic acid (DHA) are both known to exert cardiovascular health benefits 25 .
The ratio of omega-3 to omega-6 PUFA levels is generally considered to be a major determinant of cardiovascular risk. Consumption of omega-6 PUFAs in Europe, particularly linoleic acid, has increased by approximately 50% in the past 20 years, correlating
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Preclinical studies. Many in vitro and in vivo studies have shown that omega-3 PUFAs can attenuate several funda mental steps involved in atherosclerotic plaque develop ment. Omega-3 PUFAs can reduce the expression of several proatherogenic markers in both murine and human macrophages stimulated with proinflammatory cytokines 36, 37 . The attenuation of monocyte migration to the plaque has also been demonstrated in both in vitro and in vivo assays after omega-3 PUFA supplemen tation 38 . Furthermore, omega-3 PUFA treatment has been shown both to reduce the expression of genes implicated in the uptake of LDL and to increase the expression of genes involved in cholesterol efflux 39 , which might explain the observed reduction in cholesterol uptake 40 and acceleration of cholesterol efflux 41 in vitro. Ldlr-deficient mice fed a high-fat diet to mimic human atherosclerosis were supplemented with fish oil for 16 weeks in a study by Brown and colleagues 38 . The fish-oil-treated mice had significantly reduced plasma cholesterol levels and smaller atherosclerotic plaques compared with the control group 38 , attributable to a 50% decrease in monocyte migration into the atherosclerotic lesion. However, the same study reported no differences in lesion size or monocyte migration after fish oil supplemen tation in Apoe-deficient mice 38 . In a separate study, investigators fed Ldlr-deficient mice with a high-fat diet for 8 weeks before switching to a normal diet with or without 5% EPA for an additional 4 weeks 42 . EPA supplementation increased plasma HDL levels and caused the plaque to regress by 21% in size. Furthermore, the expression of several proinflammatory factors including IFNγ, IL-12, tumour necrosis factor (TNF), and intercellular adhesion molecule 1 (ICAM1) were all significantly reduced in the atherosclerotic plaques of EPA-treated mice 42 . The importance of the ratio of omega-3 to omega-6 PUFAs in dictating atherosclerotic risk has been demonstrated in an Apoe-deficient mouse model that also expressed a fat-1 gene from C. elegans 43 . Fat-1 transgenic mice can metabolize omega-6 PUFAs into omega-3 PUFAs using an omega-3 fatty acid desaturase and, therefore, should have an approximate ratio of omega-3 to omega-6 fatty acids of 1:1 (REF. 43 ). After consumption of a high-fat diet for 14 weeks, the Apoe −/− /fat-1 mice had smaller atherosclerotic lesions and reduced expression of Figure 1 | Formation of an atherosclerotic plaque. a | The expression of proinflammatory genes, including intercellular adhesion molecule 1 (ICAM1) and macrophage chemoattractant protein 1 (MCP1, also known as CCL2), is triggered by the build-up of modified LDL in the neighbouring endothelial cells during the development of the initial lesion. Circulating monocytes are recruited to the modified LDL, migrate into the intima, and then differentiate into macrophages. b | Once inside the walls of the artery, the macrophages can take up the modified LDL and become lipid-laden foam cells, which can accumulate and form a fatty streak. c | During complex lesion formation, foam cell lysis by apoptosis and necrosis leads to the formation of a necrotic core and, together with defective efferocytosis, results in the amplification of the inflammatory response. Smooth muscle cells (SMCs) begin to migrate from the media to the intima, and the extracellular matrix (ECM) forms a fibrous cap and stabilizes the plaque. SMCs also transform to foam cells. During later stages of development of the complex lesion, the plaque can become unstable owing to the inflammatory response, resulting in an inhibition of ECM formation, particularly collagen production by SMCs. The remaining ECM can then undergo degradation by proteases released by macrophages, resulting in an unstable lesion that can rupture and lead to thrombosis. These events can cause a myocardial infarction or stroke, depending on the location of plaque formation. IFNγ and monocyte chemoattractant protein 1 (MCP1; also known as C-C motif chemokine 2) compared with the Apoe −/− littermates 43 . However, no differences in the plasma levels of LDL, HDL, or total cholesterol were observed between the two groups. Together, these preclinical data support increased consumption of omega-3 PUFAs either through the diet or through EPA dietary supplementation for the prevention of atherosclerosis.
Clinical studies. The cardiovascular benefits of omega-3 PUFAs have also been demonstrated in humans. A meta-analysis published in 2015 reported that increased EPA and DHA consumption -through either supplementation or consumption of enriched foods -was associated with decreased blood triacyl glycerol levels in healthy individuals or in patients with marginal hyperlipidaemia 44 . Omega-3 PUFAs have been shown to be beneficial for individuals suffering from hypertriglyceridaemia, and have very few adverse effects 45 . A cohort of 600 men with CVD who received fish oil supplementation showed reduced markers of atherothrombotic risk 46 . Furthermore, a separate study involving 160 Japanese patients with coronary artery disease found that low serum levels of DHA correlated with reduced endothelial function, as measured by flowmediated dilata tion 47 . This observation confirms the findings from an earlier study that reported an improvement in endo thelial function and arterial stiffness, as measured by flow-mediated dilatation and pulse wave velocity, respectively, in 29 patients with metabolic syndrome after 12 weeks of daily omega-3 PUFA intake 48 . Over the past 30 years, three large trials have been performed to assess the cardiovascular benefits of EPA and DHA supplementation: the DART trial 49 , GISSIPrevenzione trial 50 , and the JELIS trial 51 . Investigators in the DART trial 49 , published in 1989, recruited 2,033 men with a recent history of MI and randomly allocated them to receive advice or no advice on each of three dietary factors: reduced fat intake to increase the ratio of polyunsaturated fat to saturated fat; increased omega-3 PUFA intake either in the form of oily fish or fish capsules; and increased cereal fibre intake. After a 2-year follow-up period, the cohort of patients who were advised to increase omega-3 PUFAs in their diet had a significant 29% reduction in mortality compared with those who did not 49 , which was largely attributable to a reduction in cardiovascular events. No differences in mortality were observed in patients allocated to receive the other dietary advice 49 . Investigators in the subsequent GISSI-Prevenzione trial 50 , published in 1999, recruited 11,324 patients with recent MI and randomly assigned them to receive omega-3 supplements (1 g per day), vitamin E, both, or none for 3.5 years. The primary end point of the study was a composite of death, nonfatal MI, and stroke. After 6 months, the study found no clinically significant changes in the serum levels of total cholesterol, LDL choles terol, or HDL cholesterol between all four groups 50 . However, by the end of the study, patients receiving omega-3 PUFA supplementation, but not vitamin E, showed a 15% reduction in the primary end point of the study. Furthermore, the incidence of sudden cardiac death was 45% lower in patients treated with omega-3 PUFAs than in the control group 50 . Together, these two large trials support the use of omega-3 PUFAs in the context of MI.
The benefit of adding EPA to statin therapy has also been evaluated. In a study published in 2007, a total of 18,645 patients with hypercholesterolaemia recruited for the JELIS trial 51 were randomly assigned to statin therapy combined with EPA supplementation, or statin-only therapy. After an average follow-up of 4.6 years, a 19% relative reduction in major cardiovascular events was observed in patients receiving EPA plus statin compared with statin alone. However, EPA supplementation did not increase serum HDL levels or reduce serum LDL levels 51 . In a study published in 2016, 95 patients who had been receiving statin treatment for a minimum of 52 . Furthermore, patients receiving EPA had reduced levels of pro inflammatory cytokines, including MCP1 52 . These clinical trials provide support that increasing omega-3 PUFA levels, particularly via EPA supplementation, alone or in combination with statin therapy, can substantially reduce cardiovascular risk.
Despite the promising results discussed thus far, the benefits of omega-3 PUFA supplementation on cardiovascular health remain inconclusive, given the conflicting results in the literature. In 2014, a meta-analysis that included five trials enrolling a total of 396 participants found no evidence of a protective association between omega-3 PUFA supplementation and reduced major adverse cardiac events in individuals with peripheral artery disease 53 . A systematic review that included 48 randomized, controlled trials (n = 36,913 individuals) and 41 cohort studies also did not detect any significant reductions in cardiovascular death in patients receiving omega-3 supplementation for 6 months 54 . A metaanalysis that specifically focused on patients with a history of CVD was also unable to identify any cardioprotective benefits of omega-3 PUFA supplementation in 14 randomized double-blind trials that recruited 20,485 participants in total 55 . A further meta-analysis also failed to demonstrate any association between omega-3 supplementation and mortality risk after evaluation of 20 randomized clinical studies that included 68,680 individuals 56 . However, care must be taken when interpreting the results of these clinical trials, owing to the heterogeneity within the designs of the studies 53 . One difference between the trials is whether omega-3 PUFAs were administered alone or in combination with statins, which together might have exerted synergistic effects. In addition, dose and intervention time periods differ between the trials. Furthermore, one important difference between the trials is the study populations used. For example, the consumption of omega-3 PUFAs is approximately 15-fold lower among individuals living in Western countries than those in Japan 57, 58 . All these factors are likely to affect the outcomes of the trials, and are attributable to the inconsistent results found within the clinical trials and meta-analyses.
Two ongoing trials aimed at assessing the cardioprotective benefits of omega-3 PUFA supplementation are the REDUCE-IT trial 59 and the STRENGTH trial 60 . The REDUCE-IT trial 59 , scheduled to be complete by 2017, has an estimated enrolment of 8,000 participants and is designed to investigate the efficacy of Vascepa (icosapent ethyl; Amarin), a purified ethy ester of EPA, for the treatment of hyperglyceridaemia. The primary aim of the trial is to evaluate whether combined Vascepa and statin therapy can further reduce the incidence of cardiovascular events compared with statin-only treatment. The secondary aim of the study is to evaluate the effect of combined therapy on serum lipid and lipoprotein levels 59 . The STRENGTH trial 60 , which is scheduled to be published in 2019, is designed to assess the efficacy of combined statin and Epanova (an omega-3 car boxylic acid; AstraZeneca) therapy in an estimated 13,000 individ uals. These two new large clinical trials will hopefully provide more insight into whether omega-3 PUFA supplementation can reduce the residual risk of CVD present in patients treated with statin.
Omega-6 polyunsaturated fatty acids Although a high intake of omega-6 PUFAs is traditionally thought to promote inflammation and contribute to disease progression, not all omega-6 PUFAs are associated with detrimental effects. The AHA currently recom mends that omega-6 PUFAs should make up 5-10% of the energy intake of an individual's diet, provided other AHA dietary and lifestyle guidelines are followed, because omega-6 PUFA intake lower than this range is thought to be more likely to increase rather than reduce the risk of cardiovascular events 61 . One important omega-6 PUFA that is considered to have anti atherogenic effects is dihomo-γ-linolenic acid (DGLA), which can be metabo lized after consumption into prostaglandin E 1 (PGE 1 ), a potent antiathero genic compound 35 . Pretreating murine macrophages with DGLA resulted in a dosedependent increase in prostaglandin levels -primarily PGE 1 and prostaglandin D 1 -after lipopolysaccharide stimulation 62 . PGE 1 can improve athero sclerotic plaque stabil ity by increasing the thickness of the fibrous cap in a dose-dependent manner in rabbits with a vulnerable plaque induced by balloon injury and a high-cholesterol diet 63 . The right balance of omega-3 and omega-6 PUFAs is essential for optimal cardiovascular health, because they can interact and influence the metabolism of one another 35 . DGLA can increase the conversion of EPA into prosta glandin I 3 , a potent vasodilator and platelet antiaggregator 64 , whereas EPA inhibits DGLA conversion to arachidonic acid, resulting in higher tissue levels of DGLA 35 . DGLA is subsequently metabolized into a variety of products, in particular PGE 1 . Apoe-deficient mice receiving a 0.5% DGLA diet for 6 months showed a significant increase in vasodilatation and a reduction in mRNA levels of ICAM1 and vascular cell adhesion molecule (VCAM)-1 (REF. 65 ). DGLA supplementation was also associated with a decrease in plaque size, exemplified by a reduction in lipid accumulation, monocyte and macrophage number, and migration of vascular smooth muscle cells 65 . Furthermore, diets that are enriched in γ-linolenic acid (GLA), a precursor of DGLA during omega-6 PUFA metabolism, have also been shown to reduce blood pressure in spontaneously hypertensive rats 66 . Clinical studies. Several observational studies have reported a reduction in omega-6 PUFAs in patients with atherosclerosis. Luostarinene and colleagues compared the make-up of fatty acids in the phospholipid fraction of human coronary arteries between aged-matched patients who died from ischaemic heart disease and patients who died from other noncardiovascular causes, and found a reduced proportion of both omega-3 and omega-6 PUFAs in those who had died from a cardio vascular event 67 . In a separate study, the lipid profile of 668 aortic plaques from 30 men who died from ischaemic heart disease were analysed and compared with their undisrupted plaques 68 . The concentration of all fatty acids was significantly increased at the edge of the disrupted plaques compared with the central region of the plaque; however, the proportion of omega-6 PUFAs as a percentage of total fatty acid concentration was significantly lower, suggesting possible oxidation of PUFAs 68 . Low serum levels of GLA have been correlated with peripheral artery disease in a cohort of 474 participants 69 . Combined GLA and EPA therapy significantly reduced blood pressure levels in individuals with lower limb atherosclerosis after 2 years compared with the placebo-treated cohort 70 . A small study also reported a decrease in serum triacylglycerol, total cholesterol, and LDL levels, as well as an increase in serum HDL levels after daily GLA consumption for 4 months in patients with hyperlipidaemia 71 . By contrast, an epidemiological study involving 2,206 Japanese men found that increased serum levels of omega-6 PUFAs were associated with increased arterial stiffness, in addition to higher serum C-reactive protein (CRP) levels 72 . A further study involving 501 participants also linked increased serum levels of omega-6 PUFAs with increased arterial stiffness 73 , whereas a smaller randomized, double-blind trial reported that daily DGLA administration for 4 weeks did not exert any antithrombotic effects 74 . Given these mixed findings, whether DGLA or GLA supplementation can prevent atherosclerosis or reduce the risk of a cardiovascular event in individuals who already have atherosclerosis remains controversial, emphasizing the need for further studies.
Although DGLA and GLA are products of linoleic acid metabolism, linoleic acid supplementation has not always convincingly been associated with cardioprotective effects. Linoleic acid supplementation did not improve arterial stiffness, blood pressure levels, serum lipid concentrations, or serum CRP levels after 6 months in individuals who were overweight 75 . However, re-evaluation of the Minnesota Coronary Experiment, performed in 1968 involving 9,570 participants, found that replacing saturated fat with linoleic acid reduced serum cholesterol levels, but did not reduce the risk of a cardiovascular event 76 . By contrast, an epidemiological study involving 1,813 individuals found an associ ation between higher tissue levels of linoleic acid and a decreased risk of MI 77 . However, given that linoleic acid is metabolized into GLA and DGLA, this increased tissue lino leic acid level might actually represent increased GLA and DGLA formation. DGLA and GLA might, therefore, be more suitable for use as nutraceuticals than linoleic acid.
Together, these data suggest that the use of DGLA (or its precursor GLA) as a nutraceutical might be as effective as EPA and DHA supplementation for preventing the development of atherosclerosis, given the importance of maintaining an optimal ratio of omega-3 to omega-6 PUFAs. However, the observation that omega-6 PUFAs might be associated with increased arterial stiffness is concerning, and the optimal intake of omega-6 PUFAs requires further investigation.
Hydroxytyrosol
The Mediterranean diet has long been associated with cardioprotective benefits 78 . Individuals living in countries within the Mediterranean basin consume the greatest amount of olive oil. Several epidemiological studies have reported a correlation between increased levels of olive oil in the diet and a lower risk of developing atherosclerosis and other CVDs 26, 79 . Numerous polyphenol compounds in olive oil exert anti-inflammatory effects, including oleuropein, tyrosol, and hydroxytyrosol. Oleuropein has been shown to reduce reactive oxygen species (ROS)-mediated expression of matrix metalloproteinase (MMP)-9 and cyclooxygenase-2 (COX2) in human umbilical vein endothelial cells (HUVECs) 80 . Furthermore, oleuropein and hydroxytyrosol have been shown to inhibit lipopolysaccharide-induced expression of VCAM1, ICAM1, and E-selectin in a dose-dependent manner in HUVECs 81 . However, oleuropein undergoes almost complete degradation during olive ripening and, therefore, is unlikely to contribute to the cardiovascular health benefits associated with the Mediterranean diet 82 . By contrast, hydroxytyrosol levels increase throughout the ripening process 82 , and hydroxytyrosol is, therefore, often considered to be one of the major antiatherogenic polyphenol compounds in olive oil.
Preclinical studies. Numerous in vitro and in vivo studies have assessed the use of hydroxytyrosol as a nutraceutical for atherosclerosis. Co-incubation of hydroxytyrosol with proinflammatory cytokines in HUVECs in vitro significantly reduced the expression of cell surface adhesion molecules such as VCAM1 and ICAM1 compared with incubation with cytokines alone 83 . Furthermore, hydroxytyrosol has been shown to reduce the production of several proinflammatory markers in cultures of primary human monocytes 84 . Phenolenriched olive oil significantly increased plasma HDL levels in Wistar rats that were fed olive-oil-based diets for 6 weeks 85 . Importantly, nonenriched virgin olive oil did not signifi cantly alter HDL levels, indicating that the cardioprotective effects of the olive oil were dependent on its phenol content 85 . However, neither the virgin olive oil nor the enriched olive oil altered plasma LDL levels in the rats. A subsequent study reported a decrease in total cholesterol and plasma LDL-cholesterol levels in Wistar rats fed with both virgin olive oil and cholesterol, compared with rats fed with only cholesterol after 4 weeks 86 .
Hydroxytyrosol also reduced atherosclerotic plaque size and improved antioxidant status in hyperlipaemic rabbits fed an atherogenic diet 87 . Increasing dietary intake of hydroxytyrosol might be an effective strategy to increase serum HDL levels and reduce serum oxLDL levels. However, this approach might not be effective for those already on a low-cholesterol diet. Apoe-deficient mice that were given a standard chow diet and daily hydroxytyrosol supplementation for 10 weeks showed larger atherosclerotic lesions compared with the control mice, in addition to a decrease in apolipoprotein A1 levels, an increase in total cholesterol levels, and no changes in plasma HDL levels 88 . These results indicate that hydroxytyrosol might actually enhance atherosclerosis development in those on a low-cholesterol diet. Given that the majority of patients at risk of CVD are likely already to be on a low-cholesterol diet, further in vivo studies are required to understand the effects of hydroxytyrosol supplementation when taken in combination with a low-cholesterol diet.
Clinical studies. Many clinical trials have been performed to investigate the potential health benefits of hydroxytyrosol supplementation. The randomized, crossover, controlled EUROLIVE study 89 involving 200 healthy male individuals assigned to receive olive oil with low, medium, or high phenolic content reported a linear relationship between the phenolic content of olive oil and an increase in serum HDL levels, which resulted in a decrease in the ratio of total cholesterol to HDL cholesterol. This increase in HDL-cholesterol levels was also accompanied by a decrease in triacylglycerol levels, as well as a reduction in markers of oxidative stress 89 . Consistent with this finding, two additional studies have shown that hydroxytyrosol can reduce serum oxLDL concentration in a dose-dependent manner in both healthy individuals and patients with coronary heart disease 90, 91 . Hydroxytyrosol has also been shown to exert anti-inflammatory effects (by reducing IL-6 and CRP levels) in 28 patients with stable coronary heart disease who received a daily dose of virgin olive oil (50 ml) for 21 days 92 . Furthermore, a randomized, controlled, double-blind, crossover study involving 13 individuals with prehypertension or hypertension found that intake of olive oil enriched with its own polyphenols significantly improved endothelial function and decreased oxLDL levels compared with nonenriched olive oil 93 . In 2013, the PREDIMED study 94 involving 7,447 participants at high risk of CVD reported that 5-year intake of a Mediterranean diet supplemented with either extra-virgin olive oil or nuts significantly reduced the risk of a cardiovascular event compared with a low-fat control diet. However, no differences in the total number of cardiovascular events were detected between the patients receiving olive-oil-supplemented diet and those receiving the nut-supplemented diet 94 . Earlier analysis of the PREDIMED study 95 in 187 asymptomatic high-risk patients showed a significant reduction in intima-media thickness in those with a baseline intima-media thickness of ≥0.9 mm after 1 year on a Mediterranean diet supplemented with either olive oil or nuts. However, no changes in intima-media thickness were observed in patients with baseline intima-media thickness <0.9 mm, suggesting potential benefits of the Mediterranean diet in reducing subclinical atherosclerosis in those at a greater initial risk 95 . The PREDIMED study design could have been improved with inclusion of a group receiving a Mediterranean diet not supplemented with olive oil or nuts to determine which component of the diet was associated with cardiovascular benefits.
In a separate trial, 90 participants were randomly assigned to one of three diet interventions for 3 months: regular (control) diet, Mediterranean diet plus virgin olive oil (328 mg/kg polyphenols), or Mediterranean diet plus washed virgin olive oil (55 mg/kg polyphenols) 96 . A significant reduction in serum levels of LDL, HDL, and total cholesterol were observed after 3 months in those who received the Mediterranean plus virgin olive oil diet compared with the regular diet, with no changes in the ratio of total cholesterol to HDL cholesterol or in the ratio of LDL cholesterol to HDL cholesterol 96 . The serum choles terol levels of those receiving the Mediterranean and washed olive oil were also not significantly altered; however, both Mediterranean dietary interventions signifi cantly reduced serum CRP levels when compared with their baseline levels 96 . Furthermore, consumption of the Mediterranean diet with virgin olive oil significantly reduced the expression of several proatherogenic genes compared with the control group 96 . Additionally, consumption of polyphenol-enriched olive oil for 4 months resulted in a significant improvement in endothelial function, as well as a decrease in several inflammatory markers, including serum ICAM1 levels and monocyte number 97 . Together, these clinical studies highlight the potential antiatherogenic properties of hydroxytyrosol when added to the diet.
Allicin Allicin (diallyl thiosulphinate) is a natural organic sulphur-containing compound found in garlic. When fresh garlic is crushed, alliin is converted into allicin by the enzyme alliinase. The newly formed allicin is highly unstable and rapidly breaks down into several smaller polysulphides that can form hydrogen sulphide (H 2 S) in a thiol-dependent manner in cells 98 . The antiatherogenic and anti-inflammatory health benefits of garlic are attributable to this formation of H 2 S.
Preclinical studies. The benefits of treatment with H 2 S donors (compounds that can be broken down into H 2 S) have been observed in both in vitro and in vivo studies. The treatment of lipopolysaccharide-stimulated murine macrophages with sulphur-containing compounds originating from garlic has been shown to attenuate the expression of several proinflammatory cytokines, including IL-1β, IL-6, and TNF
99
. The anti-inflammatory properties of H 2 S donors have also been observed in vivo using murine models, which demonstrate inhibition of leukocyte adherence to the endothelium, indicative of a reduction in inflammation 100 . In addition to diminishing the initial inflammatory response, H 2 S has also been shown to attenuate p38 mitogen-activated protein kinase activation and caspase 3 cleavage, which results in accelerated resolution of inflammation by stimulating the short-term survival of neutrophils 101 . H 2 S donors are thought to have potent antioxidant effects, because many studies have shown that H 2 S donors can reduce lipopolysaccharide-stimulated indu cible nitric oxide synthase and COX2 expression, which consequently diminishes ROS production in vitro 99, 102 . Furthermore, H 2 S donors have been shown to reduce foam cell formation by attenuating the expression of MSR1, sterol O-acyltransferase 1 (also known as ACAT1), and CD36 in human monocyte-derived macro phages, possibly through the ATP-sensitive K + channel (K ATP ), and mitogen-activated protein kinase 1 and 3 pathways 103 . ACS14 (2-acetyloxybenzoic acid 4-[3-thioxo-3H-1,2-dithiol-5-yl]phenyl ester) is a novel H 2 S-releasing aspirin that has been used to study the effects of H 2 S donors on atherosclerotic plaque development in Apoe-deficient mice 104 . Mice supplemented with ACS14 developed smaller atherosclerotic lesions compared with mice receiving the equivalent dose of regular aspirin, possibly attributable to reduced monocyte migration into the plaque 104 . Apoe-deficient and Ldlrdeficient mice administered with pure allicin for 8 weeks also showed a reduction in plaque size by approximately 69% and 57%, respectively, compared with placebo 105 .
Clinical studies. The benefits of garlic supplementation have also been observed clinically. In a study involving 152 participants, high-dose dietary garlic supplementation (900 mg garlic powder per day) for 48 months signifi cantly attenuated atherosclerotic lesion volume by 6-18% 106 . A subsequent preliminary study showed that adding aged garlic extract to statin therapy slowed the rate of atherosclerotic development by reducing coro nary calcification compared with statin-only therapy 107 . A meta-analysis of 45 trials found that garlic sup plementation also reduced serum levels of LDL, triacyl glycerol, and cholesterol after 1-3 months, but not after 6 months 108 . Furthermore, garlic did not significantly improve blood pressure. The effect of garlic supplementation on clinical outcomes was not analysed owing to the lack of robust, long-term trials, emphasizing the need for large clinical trials to evaluate the potential of garlic as a nutraceutical. Notably, a randomized clinical study involving 192 patients with hypercholesterolaemia assigned to receive garlic in three different forms (aged garlic extract, raw garlic, or garlic powder) or placebo found no differences in LDL or HDL levels between treatment groups 109 . However, allicin might exert its cardioprotective effects via other mechanisms, such as by reducing ROS production and attenuating proinflammatory gene expression, rather than directly altering the ratio of LDL to HDL in the bloodstream.
Phytosterols
Phytosterols are steroid compounds found in plant sources and are similar in structure to cholesterol. Diets rich in phytosterols have long been associated with reduced plasma LDL levels 110, 111 . Phytosterols are thought to exert their cardioprotective effects by competing with cholesterol in the lumen of the intestine during dietary and biliary cholesterol uptake Phytosterols can mediate strong anti-inflammatory effects in vivo. This effect has been demonstrated in Apoedeficient mice fed a high-fat diet supplemented with 2% phytosterols for 2 weeks, and then injected with ovalbumin to trigger an inflammatory response to a foreign antigen 113 . The spleen cells from phytosterol-treated mice showed reduced production of pro inflammatory cytokines IL-6 and TNF, and increased production of the anti-inflammatory cytokine IL-10 compared with the spleen cells from mice on the control diet 113 . In addition, atherosclerotic lesion size was 60% smaller in mice on the phytosterol-enriched diet 113 . After 14 weeks on a diet supplemented with 2% phytoster ols, Apoe-deficient mice showed alterations in the expression of 132 genes, including several hepatic genes associated with the regulation of sterol metabolism 114 . These changes in gene expression might provide an insight into how phytosterols mechanistically exert their cardioprotective effects. However, further studies are required to determine the link between altered gene expression patterns and their antiatherogenic properties. In a separate study, the atherosclerotic lesions of Apoe-deficient mice fed a high-fat diet supplemented with a 2% phytosterols for 20 weeks were reduced by approximately 50% compared with Apoedeficient mice fed a high-fat control diet 115 . Furthermore, phytosterol supplementation has been associated with reduced hepatic lipase activity and plasma fibrinogen concentrations, in addition to a small increase in HDLcholesterol levels 115 . Consistent with these findings, subsequent studies also reported smaller atherosclerotic lesions and lower plasma LDL levels in Apoe-deficient mice fed a 2% phytosterol-supplemented diet 116, 117 . Clinical studies. Several clinical studies have assessed the benefits of phytosterol-enriched diets in humans. An epidemiological study involving 22,256 participants found a correlation between diets with high levels of phytoster ols and low levels of serum LDL 111 . Furthermore, a smaller study involving patients with hypercholesterolaemia reported a significant reduction in serum LDL levels with 12 weeks of phytosterol supplementation, although no changes in flow-mediated dilatation or pulse-wave velocity were observed 118 . A meta-analysis published in 2016 that included 20 randomized, controlled trials and 1,308 participants found an association between regular phytosterol intake and reduced serum LDL levels 119 . However, the study found no correlation between phytosterol consumption and plasma CRP levels 119 , highlighting the need for further research to assess the effects of phytosterol dietary supplementation on inflam mation. Nevertheless, owing to the LDL-lowering effects of phytos terols, the European Atherosclerosis Society consensus panel recommended the use of phyto sterol supplementation in the following individuals: those at low or intermediate risk of CVD, but who do not meet requirements for traditional pharmaceutical therapies; those with familial hypercholesterolaemia; or those who are unable to achieve target LDL levels with statin therapy 120, 121 .
The method of phytosterol delivery is also thought to effect its LDL-lowering properties. For example, one study found that ingestion of phytosterol capsules did not reduce plasma LDL levels in patients with hypercholesterolaemia 122 . However, other studies have reported no differences in the LDL-lowering properties of phytosterol capsules and phytosterol-rich foods 123 . Further studies are required to assess whether the effectiveness of phytosterol supplementation can be altered by the delivery method.
Despite the reported beneficial effects of phytosterols, other studies have also suggested that high levels of phytosterol in the diet might actually be detrimental and contribute to the development of atherosclerosis 124 . In a study involving 109 postmenopausal women, an increased ratio of phytosterol to cholesterol was associated with a higher risk of developing coronary heart disease 125 . However, many studies claiming that phytosterols can increase the risk of cardiovascular events often lack appropriate controls or fail to match serum LDL levels between cases and controls and, therefore, their findings must be interpreted with caution 124 . For example, Assmann and colleagues reported that serum phytosterol levels were significantly higher in 159 participants who had suffered from a MI or sudden cardiac death compared with 318 healthy individuals 126 . However, the study did not match blood pressure and LDL-cholesterol, total-cholesterol, and triacylglycerol levels between the two groups, all of which are risk factors for cardiovascular events 124 . Given that the ratio of phytosterol to cholesterol between the two groups was not significantly different, the study did not provide conclusive evidence that the cardiovascular events were directly linked to increased phytosterol levels 124 .
Flavanols
Flavanols, a subclass of flavonoids, are secondary plant metabolites that are commonly found in fruit and vegetables 127 . Given that a diet rich in fruit and vegetables is linked with cardiovascular benefits, flavanol supplementation is a promising avenue as a nutraceutical for the prevention of atherosclerosis 24 . Catechin is a major flavanol present in green tea and cocoa that has been found to reduce endothelial exocytosis 128 , a process by which activated endothelial cells can release pro inflammatory cytokines and chemokines, which are usually stored in intracellular endothelial granules, into the extracellular space 128 . Catechins might, therefore, have a role in reducing vascular inflammation during the development of atherosclerosis.
Preclinical data. Apoe*3-Leiden mice fed a high-fat diet supplemented with 0.1% epicatechin (cis configuration isomer of catechin) for 20 weeks showed attenuation of atherosclerotic lesion area with no effect on plasma lipid levels 129 . Furthermore, a microarray analysis also revealed that epicatechin supplementation resulted in an alteration in the gene expression of 173 genes compared with no supplementation, including 77 that seemed to be inversely regulated 129 . A substantial number of these genes were involved in cell migration 129 , highlighting a possible mechanism by which epicatechin can reduce lesion size.
Clinical data. An increase in nitric oxide production has been observed in a small clinical study in which 27 healthy individuals consumed a flavanol-rich diet consisting of cocoa (epicatechin and catechin) for 5 days 130 . This increase in nitric oxide production was accompanied by an increase in vasodilatation. 130 . Other studies have since confirmed the vasodilatory properties of flavanols, in addition to observing a reduction in circulating oxLDL levels after 5 weeks of flavanol supplementation in the form of green tea extract 131, 132 . Daily catechin consumption for 24 weeks also significantly reduced circulating LDL levels in obese or near-obese children 133 . Furthermore, consumption of cocoa flavanol-rich supplements for 30 days improved flow-mediated dilatation in 57 patients with end-stage renal disease 134 , highlighting its use in a population with endothelial dysfunction at high risk of developing CVD. Consumption of flavanol-rich chocolate was also associated with improved flow-mediated dilatation in a trial of 20 patients with congestive heart failure 135 .
Many other studies have also demonstrated the cardio protective effects of cocoa flavanols in healthy individuals. Daily cocoa flavanol supplementation for 30 days improved vascular function in 100 healthy individ uals without a history of CVD 136 . Additionally, the consumption of cocoa flavanols for 14 days improved flow-mediated vasodilatation and reduced arterial stiffness in both young and elderly healthy partici pants 137 . Furthermore, consumption of a green tea extract attenuated the levels of several pro inflammatory mediators, including Fas ligand, IL-6 receptor, IL-8, soluble TNF-receptor 2, and neutrophil-activating peptide 138 . The ratio of total cholesterol to HDL cholesterol was also signifi cantly reduced in 17 healthy men after daily catechin supplementation for 3 weeks, suggesting that catechin might be useful for the prevention of atherosclerosis 139 . However, the same study found no reduction in other markers of cardiovascular risk, such as blood pressure 139 . Although another study investigating the intake of daily cocoa flavanol for 4 weeks showed no improvements in blood pressure and flow-mediated dilatation in 30 participants who were overweight, a significant improvement in arterial stiffness was found in the female participants 140 . The lack of improvement in blood pressure parameters in these two studies contradicts previous findings [130] [131] [132] ; this discrepancy might be attributable to the small number of individuals who partici pated in these trials. Together, these data suggest that flavanols might exert their cardio vascular health benefits by lowering circulating LDL levels and improving vasodilatation.
Vitamins C and E
Given that the human body is unable to store vitamin C (also known as ascorbic acid), foods rich in vitamin C, such as oranges, orange juice, broccoli, and black currants, must form part of the daily diet. Increased intake of vitamin C has long been associated with a decrease in the prevalence of coronary artery disease 141 . Vitamin E is also thought to be cardioprotective, given its primary function as an antioxidant.
Preclinical studies. Numerous in vivo studies have shown that vitamin C supplementation can improve endothelial function 142, 143 . Apoe-deficient mice supplemented with 1% vitamin C for 26-28 weeks were found to have restored endothelial nitric oxide synthase activity and increased tetrahydrobiopterin levels in the aorta compared with the control Apoe-deficient mice 142 . A subsequent study supported these findings by demonstrating that vitamin C supplementation in Apoe-deficient mice fed a high-fat diet inhibited hypercholesterolaemia-induced endothelial dysfunction of the carotid artery 143 . Despite such promise, the use of vitamin C as a nutraceutical for the prevention of athero sclerosis remains controversial because many studies have shown no benefit on plaque lesions or lipid profiles. Similarly, large observational studies have not demonstrated the efficacy of vitamin E supplementation in preventing CVD.
Dietary supplementation with a cocktail of antioxidants (vitamin E, vitamin C, and β-carotene) in Apoedeficient mice did not reduce lesion size or alter plasma lipid profile 144 . However, this study involved older mice (aged 20 weeks), whereas the previously mentioned positive mouse studies were performed in much younger mice (aged 4-5 weeks 142, 143 ), suggest ing that age might influence the cardiovascular health benefits of vit amin C and vitamin E supplementation in Apoe-deficient mice. Consistent with this observation, vitamin C and vitamin E supplementation in Apoe-deficient mice aged 50-60 weeks did not significantly reduce angio tensin IIinduced plaque rupture 145 . By contrast, vitamin E supplementation in Apoe-deficient mice aged 26 weeks prevented angiotensin II-mediated plaque rupture 146 .
Clinical studies. Low serum vitamin C levels have been linked with an increased risk of cardiovascular events in humans 147 . Vitamin C can exert its cardiovascular bene fits by mitigating inflammatory and oxidative stresses mediated by a high-fat and high-carbohydrate diet by preventing an increase in endotoxin and Tolllike receptor expression 148 . Others have reported that vitamin C can improve vasodilatation in patients with coronary artery disease 149 and in smokers 150 , thereby resulting in reduced blood pressure, and consequently reduced risk of cardiovascular events. In 2014, a meta-analysis based on 44 clinical trials found a positive association between vitamin C supplementation and improved endothelial function in patients with atherosclerosis 151 . In addition, the ASAP trial 152 involving 520 participants showed a significant attenu ation in the progression of atherosclerosis in men after treatment with combined supplementation of vitamin C and vitamin E twice per day for 3 years. However, individ ual supplementation with vitamin C or vitamin E did not reduce intima-media thickness, and the combined supplementation did not reduce atherosclerosis progression in women 152 . A pooled analysis of nine studies showed an association between high vitamin C supplementation and a reduced risk of cardio vascular events 153 . However, the same analysis also found that high vitamin E intake was not associated with any cardioprotective effects 153 . By contrast, the CHAOS trial 154 involving 2,002 patients with established athero sclerosis found that daily vitamin E supplementation reduced the risk of nonfatal MI compared with those receiving the placebo after 1 year. However, vitamin E supplementation did not reduce cardio vascular deaths 154 . Furthermore, combined vitamin C and vitamin E supplementation every day for 8 weeks in 30 men with hypertension significantly improved arterial stiffness and flow-mediated dilatation, and reduced oxidative stress 155 . Despite numerous positive findings, several clinical trials to assess the benefits of vitamin C and vitamin E supplementation for atherosclerosis have produced neutral results. A randomized study designed to test an initial vitamin C dose of 2 g followed by a daily intake of 1 g in 20 young adult smokers showed improved vasodilatation after the first 2 h, but no sustained beneficial effects after 8 weeks 156 . In addition, a large-scale study involving 20,536 adults in the UK with either coro nary artery disease, peripheral occlusive artery disease, or diabetes who were randomly assigned a daily dietary supplement containing vitamin E, vit amin C, β-carotene, or placebo reported no observable benefits with either treatment in terms of all-cause mortality or cardiovascular events at the 5-year follow-up 157 . Furthermore, several studies to evaluate the efficacy of vitamin E specifically for the prevention of CVD also produced disappointing results. The GISSIPrevenzione trial 50 found that daily consumption of vitamin E (300 mg) did not reduce the risk of cardiovascular events. The HOPE study 158 , which involved 9,541 participants considered to be at high risk of a cardiovascular event, reported no changes in cardiovascular mortality after daily vitamin E consumption for 4.5 years. Conversely, the VEAPS trial 159 observed a decrease in plasma oxLDL levels and reduced vulnerability of LDL to oxidation in 353 individuals after daily vitamin E supplementation for 3 years. However, this trial also showed no changes in intima-media thickness with vitamin E supplementation 159 . Although both vitamin C and vitamin E were previously considered ideal nutraceuticals for the prevention of atherosclerosis owing to their antioxidative and anti-inflammatory properties, they have not been proven to be consistently effective in the long-term prevention of CVD. Consequently, the AHA advisory panel in 2004 recommended against using vitamin supplements to reduce the risk of cardiovascular events 160 .
Dietary fibre
Dietary fibre can be fermented by the gut microbiota in the intestine to produce a variety of short-chain fatty acids that can exert antiatherogenic properties. Butyrate is a short-chain fatty acid produced during fibre fermentation shown to have anti-inflammatory properties 161, 162 . Preclinical studies. Butyrate treatment of murine macrophages stimulated with lipopolysaccharide have reduced proinflammatory cytokine production, including IL-1β, IL-6, and TNF, and attenuated nitric oxide production 162 . Furthermore, HUVECs treated with butyrate for 24 h showed increased ICAM1 expression, but no changes in VCAM1 expression 163, 164 . However, preincubation of HUVECs with butyrate attenuated TNF-induced expression of VCAM1, which correlated with a decrease in monocyte adhesion to endothelial cells 164 .
In vivo studies have also demonstrated the benefits of butyrate in preventing atherosclerosis. Apoe-deficient mice fed a chow diet supplemented with 1% butyrate for 10 weeks developed smaller and more stable lesions compared with those fed a control diet 165 . Lesions were reduced by approximately 50% owing to attenuated monocyte and macrophage migration towards the site of the plaque, together with lower levels of VCAM1 and MCP1 expression in the lesion 165 . Furthermore, the lesions in the butyrate-supplemented mice were composed of more ECM compared with the control mice, which is an indicator of increased plaque stability.
Clinical studies. The relationship between increased fibre intake and reduced CVD has been well established. A 6-year follow-up study involving 39,876 female partici pants found that higher fibre intake was associated with a lower risk of MI and CVD after adjusting for age and other treatments received 166 . However, this relation ship was no longer significant after controlling for other confounding variables. Another study involving 46,032 men found that increased dietary intake of fibre was significantly linked with reduced risk of peripheral artery disease over a 12-year follow-up period, even after adjusting for all other factors 167 . Increased dietary fibre has also been linked to a lower risk of haemorrhagic stroke 168 . Furthermore, a meta-analysis of 10 cohort studies involving 91,058 men and 245,186 women reported an inverse relationship between increased diet ary fibre intake and cardiovascular risk 169 . For every 10 g per day increase in dietary fibre, there was a 14% and 27% decrease in the risk of a cardiovascular event and coronary death, respectively, over a 6-10 year follow-up period 169 . However, addition of fibre to statin and/or ezetimibe therapy did not prov ide extra cardiovascular health benefits to patients with hypercholesterol aemia, but improved blood glucose levels and reduced BMI 170 . Notably, given that this study did not include a fibre-only treatment group, it is not pos sible to deline ate the effects of fibre that are independent of the lipid-lowering therapy.
Other less-studied nutraceuticals Carnosine. Carnosine, a known antioxidant 171 , is a dipeptide formed from histidine and β-alanine, and is commonly found in meat. Carnosine has been shown to reduce the glycation of LDL in human monocytederived macrophages, resulting in reduced intra cellular cholesterol accumulation and attenuated foam cell forma tion 172 . This process is important in patients with diabetes because they are at increased risk of developing atherosclerosis. Apoe-deficient mice with diabetes supplemented with carnosine through their diet for 20 weeks showed an improvement in important indicators of atherosclerotic plaque stability 173 . Although carno sine did not reduce plaque size, it stabilized the lesion by increasing collagen content by 50% and reducing lipid-filled plaque area by 60% 173 . However, the number of macrophages within the plaque was also increased by ~70% 173 , indicating plaque instability. Furthermore, 6-week carnosine supplementation in Sprague-Dawley rats significantly improved serum HDL levels and reduced serum LDL levels; however, the levels of total cholesterol and triacylgycerols were unchanged 174 . The same study also found that carnosine supplementation increased serum levels of superoxide dismutase while simultaneously decreasing plasma malondialdehyde levels (a marker of lipid peroxidation), suggesting that caronsine might exert its cardioprotective effects through its antioxidative properties 174 . A double-blind, randomized, pilot trial also found that daily carnosine supplementation for 12 weeks in individ uals who were overweight or obese significantly improved insulin resistance; however, no improvement in blood pressure, serum cholesterol, or CRP levels were observed 175 . Carnosine might, therefore, be a promising nutraceutical for patients with diabetes at risk of atherosclerosis, but further studies are required to elucidate its effect on plaque stability. Given the lack of in vivo and clinical data directly linking carnosine supplementation with antiatherogenic effects, its use as a nutraceutical for patients with atherosclerosis remains limited.
Coenzyme Q 10 . Coenzyme Q 10 (CoQ 10 ) is an antioxidant present in many food sources and has an important role in the mitochondrial electron transport chain. Given that CoQ 10 and cholesterol synthesis share the same intermediate steps in their respective biosynthetic pathways, patients receiving statin treatment have reduced CoQ 10 levels 176 . In an in vivo study involving Apoe-deficient mice receiving CoQ 10 dietary supplementation for 4 weeks, CoQ 10 treatment attenuated LDL oxidation and reduced foam cell formation 177 . These effects were achieved by enhancing the reverse cholesterol transport process via microRNA-378, resulting in increased cholesterol efflux from the cell and decreased formation of foam cells 177 . Furthermore, the plaque size of the mice receiving CoQ 10 was significantly smaller compared with the control group. By contrast, in another in vivo study involving Apoedeficient mice, CoQ 10 supplementation for 15 weeks did not reduce lesion size in cigarette-smoke-enhanced atherosclerotic development 178 . CoQ 10 supplementation has also been shown to increase cholesterol efflux in human monocyte-derived macrophages ex vivo 179 . In a small study with 20 healthy participants who were given either placebo or CoQ 10 supplements twice per day for 1 week, CoQ 10 intake significantly increased cholesterol efflux from macrophages, which correlated with an increase in the expression of the ABCG1 gene implicated in the promotion of cholesterol efflux 179 . Futhermore, CoQ 10 supplementation has been linked with a reduction in the plasma levels of proinflammatory markers such as TNF, IL-6, and MMP9, but not with any changes in anti-inflammatory markers such as IL-4 and TGFβ 180 . A meta-analysis of five trials involving a total of 194 partici pants concluded that CoQ 10 supplementation signifi cantly improved endothelial function 181 . In addition, daily dose of CoQ 10 for 8 weeks in participants with left ventricular systolic dysfunction improved flow-mediated dilatation, but did not reduce blood pressure or CRP levels 182 . CoQ 10 supplementation for 12 weeks also did not improve arterial stiffness or serum levels of oxLDL and CRP in participants who were obese 183 . The randomized, double-blind FAITH trial 184, 185 involved 65 firefighters considered to have a high cardio vascular risk (owing to occupational stress) taking a daily combined CoQ 10 and garlic supplement for 1 year. The combined supplement significantly reduced serum CRP levels and improved both pulse-wave velocity and endothelial function compared with placebo 184, 185 . However, because the study did not include a garlic-only or CoQ 10 -only group, whether the cardio protective effects were attributable to only one of the nutraceuticals or the combined supplement could not be concluded. Overall, given that the de novo synthesis of CoQ 10 is reduced by statin therapy, CoQ 10 might be a promising nutraceutical to take in combination with statins to reduce atherosclerotic development further. However, the lack of consistent studies demonstrating the benefit of CoQ 10 supplementation for prevention of atherosclerosis has limited its use as a nutraceutical at present.
Curcumin.
Curcumin is the active component of turmeric and is the dietary pigment which gives curry its orange colour. Curcumin has been shown to reduce phorbol-12-myristate-13-acetate (PMA) and lipopolysaccharide-induced expression of major proatherogenic cytokines such as MCP1, IL-1β, and TNF in primary human monocytes 186 . Curcumin can mediate the polarization of the anti-inflammatory M2 phenotype in murine macrophages 187 . Consumption of a tumeric extract for 7 weeks reduced the susceptibility of LDL to oxidation in rabbits fed a diet containing lard and cholesterol 188 . In addition, 30-day turmeric supplementation in high-fat-fed rabbits reduced the size of the fatty streak 189 . A 50% reduction in atherosclerotic lesion size was observed in Apoe and Ldlr double-knockout mice after a daily dose of 0.3 mg of curcumin for 4 months 190 . The benefit of curcumin in patients at risk of atherosclerosis has also been described. A randomized, double-blind trial involving 240 individuals with type 2 diabetes reported a decrease in cardiovascular risk with 6 months of curcumin dietary supplementation, indicated by a lower pulse-wave velocity and improved meta bolic profile 191 . Furthermore, the use of curcumin for 8 weeks improved flow-mediated dilatation in 32 postmenopausal women 192 . Interestingly the same study also found that the improvement in flowmediated dilatation was similar in women who did not receive supplement, but who exercised for 8 weeks instead 192 . A major limitation to using curcumin as a nutraceutical is its poor bioa vailability, owing to inadequate absorption in the gut, because it is rapidly broken down and excreted from the body 193 . Several strategies to increase the bioavailability are being pursued, including the use of liposomal curcumin, nanoparticles, and a curcumin-phospholipid complex 193 .
Lycopene. Lycopene is the carotenoid that gives tomatoes their bright red colour. Several epidemiological studies have found an association between diets rich in lycopene and a reduced incidence of CVD 194, 195 . Lycopene might exert its antiatherogenic effects by inhibiting de novo cholesterol synthesis, as demonstrated in vitro using murine macrophages 196 . By contrast, another in vitro study reported that LDL isolated from human donors and enriched with lycopene before being co-incubated with human endothelial cells actually increased its susceptibility to oxidation 197 . In a randomized clinical study involving 144 participants with subclinical atherosclerosis, combined dietary supplementation of 20 mg lutein (another carotenoid with potential cardioprotective effects) and 20 mg lycopene for 12 months significantly reduced carotid intima-media thickness 198 . Given that the combination of lutein and lycopene supplementation was more effective than lutein alone, a synergistic benefit of combined lutein and lycopene therapy might exist. Reduced serum levels of lycopene have also been linked with increased arterial stiffness 199 . Flow-mediated dilatation was also improved in patients receiving combined lycopene and statin therapy compared with statin-only therapy 200 . However, no changes in vasodilatation were observed in healthy participants given the lycopene supplementation, possibly indicating that lycopene is only effective when taken in combination with statins, and thus highlighting a potential role for secondary prevention of atherosclerosis 200 . In the same study, arterial stiffness, CRP serum levels, and blood pressure levels were also unchanged by lycopene in either the healthy participants or patients with CVD 200 . Another clinical trial involving 225 healthy participants also found that lycopene supplementation did not reduce blood pressure or improve arterial stiffness 201 . The possible dual effect of lycopene and statin therapy requires further investigation.
Resveratrol. Although a high intake of alcohol has been associated with hypertension and elevated plasma choles terol levels, the phenomenon known as the 'French paradox' has been used to explain why the incidence of CVD is lower in France compared with other Western countries, despite a similar diet high in fat and carbohydrates 202 . Resveratrol is a natural phenol commonly found in the skin of grapes and is considered to be one of the main active compounds responsible for the cardioprotective effects of wine. Resveratrol has been shown to reduce foam cell formation by inhibiting oxLDL uptake as well as increasing cholesterol efflux in human THP-1 macrophages 203 . This increase in efflux corresponded to an elevation in the expression of important proteins involved in the regulation of cholesterol efflux 203 . Apoe*3-Leiden.Cetp mice fed a high-cholesterol diet with a 0.01% dietary supplementation of resveratrol were also found to have 50% smaller atherosclerotic lesions compared with control mice, in addition to improved lesion stability owing to an increased ratio of collagen to macrophages 204 . However, the cardio protective benefits were similar in the reservatrol-only and statin-only groups, and the combination of treatments did not provide any additional benefit 204 . After adjusting for other risk factors, one epidemiological study concluded that the lower incidence of CVD in France was attributable to their high intake of alcohol, particularly wine 202 . The GISSI-Prevenzione trial 50, 205 also reported an association between daily consumption of wine and a reduced risk of a cardiovascular event and all-cause mortality. Although resveratrol might be useful in the prevention of atherosclerosis, it might not enhance the antiatherogenic effects of statins. Large clinical trials comparing statin-only treatment versus statinplus-resveratrol treatment are needed to determine its potential as a nutraceutical.
Berberine. Berberine is a cholesterol-lowering plant alkaloid known for its anti-inflammatory and antidiabetic effects 206 . In vitro studies have reported that berberine • Improved important factors associated with plaque stability in murine diabetes-associated models of atherosclerosis 173 • Increased serum HDL and reduced serum LDL levels in rats, and increased serum superoxide dismutase levels 
Curcumin
• Decreased the production of proinflammatory cytokines in primary human monocytes 186 • Stimulated an anti-inflammatory M2 macrophage phenotype in vitro 187 • Reduced oxidative stress and LDL oxidation, in addition to reducing aortic fatty streak development 188, 189 • Reduced atherosclerotic lesion size in Apoe and Ldlr double-knockout mice after 4 months • Wistar rats fed a diet containing hydroxytyrosol had higher plasma HDL levels and lower plasma LDL levels compared with control rats 85, 86 • Attenuated atherosclerosis disease development in hyperlipaemic rabbits, shown by smaller atherosclerotic lesions 87 Lycopene Inhibited LDL oxidation and cholesterol synthesis in vitro 196 Omega-3 PUFAs • Attenuated the expression of several important atherosclerotic markers in both murine and human macrophages 36, 37 • Increased the expression of cholesterol efflux genes and decreased the expression of LDL-uptake genes 39 • Reduced atherosclerotic lesion size and increased plasma HDL levels in Ldlr-deficient mice 38, 42 Omega-6 PUFAs • Prostaglandin E 1 , a metabolite of DGLA, improved plaque stability in rabbits by increasing the thickness of the fibrous cap 63 • GLA-enriched diets after 7 weeks reduced blood pressure in hypertensive rats
66
• DGLA dietary supplementation decreased the size of atherosclerotic plaques in mice after 6 months can attenuate the expression of lipopolysaccharideinduced proinflammatory genes such as Ccl2, Il1b, Il6, and Nos2 in mouse macrophages 207 . Furthermore, berber ine can reduce macrophage migration 208 , indicating a potential role for slowing the progression of athero sclerotic development. OxLDL accumulation within human macrophages is also reduced after berberine treatment, owing to an upregulation of expression of ABCA1, an important gene implicated in the promotion of cholesterol efflux 209 . Although the expression of scaven ger receptors was unchanged, the role of berberine in increasing cholesterol efflux from human macrophages might make it a possible nutra ceutical for reducing foam cell formation. Apoe-deficient mice fed a Western diet and berberine for 8 weeks developed fewer athero sclerotic lesions and showed reduced levels of ICAM1 and VCAM1, and decreased oxidative stress compared with mice fed a control diet 210 . In addition, high-fat-fed obese mice treated with berber ine for 36 days were found to have lower levels of total choles terol 211 , which is consistent with an earlier study in human hepatic cells that described a reduction in PCSK9 expression after berberine treatment 212 . Given that PCSK9 is an inhibitor of LDLR expression, berberine treatment was also found to increase the mRNA levels of the LDLR 212 . Several clinical studies have demonstrated the effect of berberine on cholesterol levels. In a study involving 91 Chinese patients with hypercholesterolaemia, berberine supplementation twice per day for 3 months reduced serum levels of total cholesterol and LDL cholesterol, but did not alter serum HDL levels 213 . In a separate study, berberine treatment twice per day for 3 months also lowered serum total cholesterol and LDL levels, in addition to increasing serum HDL levels in 144 patients who were considered to have a low cardio vascular risk 214 . The efficacy of berberine treatment in combin ation with statin therapy has also been assessed in a study involving participants with hypercholesterol aemia who received either berberine, statins, or a combination of the two for 2 months 215 . Either statins or berberine could individually lower serum total cholesterol and LDL-cholesterol levels, and the combination of the two therapies provided an additive effect, reducing total cholesterol and LDLcholesterol levels further compared with the individual therapies 215 . A daily combin ation of berberine, red yeast rice, and policosanol for 6 weeks in 50 individ uals with hypercholesterol aemia also effectively reduced serum levels of both total choles terol and LDL, as well as improved flow-mediated dilata tion 216 . Together, these studies show that berberine has the potential to be a cholesterol-lowering nutra ceutical by either directly preventing the development of athero sclerosis, or taken in combination with statins to enhance their LDL-lowering capacity.
Limitations and future directions
The potential cardioprotective effects of all the nutraceuticals mentioned in this Review from either preclinical or human studies are summarized in TABLE 1 and TABLE 2 , respectively. One of the major challenges involved in nutraceutical research is identifying whether the cardioprotective effects of an individual's diet are attributable to a specific compound or the result of a combination of elements. Therefore, when a potential nutraceutical is identified, its effectiveness needs to be assessed using robust randomized, controlled trials before it can be reco mmended as a dietary supplement.
A possible strategy to improve the identification of novel nutraceuticals is to include preclinical studies that focus on plaque regression rather than the prevention of atherosclerosis. The outcomes of such studies can be translated to humans, because those requiring therapeutic intervention are likely already to have established atherosclerosis. A limitation inherent in preclinical studies to assess nutraceutical therapy for prevention is that the doses of nutraceuticals used in in vitro or in vivo experiments are sometimes much higher than those used in clinical trials and, therefore, nutraceuticals often show no benefit when they reach the clinical trial phase. Investigators of preclinical studies should employ a dose that is physiologically relevant to humans (that is, a dose that is found within the bloodstream after consumption), rendering the outcomes of mechanistic studies more rele vant to clinical studies. Furthermore, such trials need to be designed to investigate clinically relevant end points as well as surrogate markers, and might consider including younger participants and investigating markers of atherosclerosis regression. The development of new imaging techniques that allow the measurement of atherosclerotic plaques sizes within arteries or the identification of new biomarkers that predict atherosclerotic development will help in the design of these trials.
A major advantage of nutraceuticals is that they can be taken safely over the lifetime of an individual, whereas pharmaceutical strategies are administered only after the risk of atherosclerosis has been identified and can result in adverse effects with prolonged use. The effects of using multiple nutraceuticals in combination must be examined further to determine whether any synergistic effects exist, which could potentiate a greater reduction in the development of atherosclerosis compared with the individ ual components. Finally, nutraceuticals should not be seen as alternatives to current therapies for athero sclerosis, but rather as an additional, complementary strategy to ensure both prevention and treatment.
Conclusions
Both preclinical and clinical studies have shown that nutraceuticals can exert cardioprotective effects and reduce the risk of cardiovascular events such as MI or stroke. Further preclinical and clinical studies are required to evaluate fully the effectiveness of the nutraceuticals mentioned in this Review, and care must be taken in experimental design to ensure that the positive findings seen in preclinical models can be translated to patients. Advances in our understanding of the cardio protective properties of nutraceuticals will lead to the identification of novel treatments and prevention strategies to reduce the prevalence of atherosclerosis.
